Glonghui May 12 丨 Huadong Pharmaceutical (000963)(000963slotmachinegames.SZ) announcedslotmachinegamesOn May 11, 2024, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.(hereinafter referred to as "Zhongmei Huadong"), a wholly-owned subsidiary of the company, received the "Notice of Acceptance" issued by the State Drug Administration (NMPA)(Acceptance Nos.: CXHS2400040, CXHS2400041), Mihuantinib tablets (Miredon?, A marketing authorization application for Mifanertinib Tablets) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with an L858R substitution mutation in exon 21 of the epidermal growth factor receptor (EGFR) was accepted.
Mahuatinib tablets are a new, powerful, highly selective, and orally active irreversible EGFR/human epidermal growth factor receptor-2 (HER2) small molecule inhibitor. It is a brand new national with independent intellectual property rights. Class 1 innovative drug. By covalent binding to the kinase regions of EGFR(ErbB1) and HER2 (ErbB2), Mavatinib irreversibly inhibits tyrosine kinase autophosphorylation, leading to down-regulation of ErbB signaling, thereby inhibiting tumor growth.
